WHAT'S NEW: Since analysts' consensus 2015 revenue and profit estimates for Valeant are below the company's 2015 guidance, any additional "visibility or conviction" regarding the company's results could boost the stock, Cantor analyst Irina Rivkind Koffler stated. Valeant should be able to meet its 2015 guidance, the analyst believes. She kept a $182 price target and Buy rating on the shares. Valeant may look to buy dental device makers in accretive deals next year, Koffler predicted. Possible takeover targets for Valeant in that sector include Patterson Companies (PDCO) , Henry Schein (HSIC) , Align Technology (ALGN) , and DENTSPLY International (XRAY) , the analyst wrote. All of these companies have cost synergies and "strategic overlap" with Valeant, she stated. Patterson and Henry Schein also have veterinary businesses and Valeant has expressed interest in entering that sector, she added.
WHAT'S NOTABLE: On December 9, Reuters reported, citing unnamed sources, that Valeant was giving up its strategy of growing through acquisitions for the time being. Valeant had recently teamed with activist investor Bill Ackman on a failed attempt to acquire Allergan (AGN) , which eventually struck an alternate deal to sell itself to Actavis (ACT) . The Fly notes that Ackman's Pershing Square reported an 8.3% stake in animal health medicines company Zoetis (ZTS) on December 5.